N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 3 N=236 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Pulmonary Fibrosis
Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters
Phase 3 N=551 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks. — -207.32; -113.59 mL/year — p=0.0002
Phase 3 N=515 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -239.91; -114.65 mL/year — p=<0.0001
Phase 2 N=9 Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
IPF
Primary: Number of Participants With Respiratory and/or Hemodynamic Deteriorations — 1; 3 Participants
N/A N=204 OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Idiopathic Pulmonary Fibrosis
Primary: Idiopathic Pulmonary Fibrosis (IPF)-Related Costs — 38923.57; 22613.68; 20369.94; 37183.17 Euro (€) — p=0.0002
Phase 3 N=555 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52 — 16.5; 31.8; 22.7; 9.7 percentage of patients
N/A N=178 A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
Idiopathic Pulmonary Fibrosis · Interstitial Lung Disease
Primary: Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home…
Phase 2 N=35 Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
N/A N=34,960 Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
Lung Diseases, Interstitial
Primary: Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs) — 0.147; 0.249; 0.334; 0.395 Cumulative incidence probability
Phase 2 N=51 Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Primary: %Survival — 44; 7 percentage of participants
Phase 2 N=432 Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Primary: Rate of Decline in FVC — -0.190; -0.174; -0.210; -0.162 Liters/year — p=0.8530
Phase 2 N=147 A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks — -77.70; 2.72; -95.62; 6.10 Milliliter
Phase 2 N=71 Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Primary: Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE) — 13; 15; 15; 12 Participants
N/A N=209 IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With IPF Symptoms — 88.0; 51.8; 49.4; 42.9 Percentage of participants
N/A N=301 Investigating Idiopathic Pulmonary Fibrosis in Greece
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit — 83; 162; 13; 43 Participants
Phase 2 N=178 Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
Idiopathic Pulmonary Fibrosis
Primary: Forced Vital Capacity (FVC) at Baseline and End of Period 1 — 2.74; 2.83; 2.40; 2.57 litres — p=0.9631
Phase 3 N=180 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39
Phase 3 N=1,177 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 — -183.48; -138.60; -114.65 Milliliters (mL) — p=0.0222
Phase 3 N=435 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity (FVC) — -8.0; -10.0; -12.4 Change in Percent Predicted FVC
Phase 3 N=344 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity(FVC) — -9; -10 Change in Percent Predicted FVC
Phase 2 N=143 Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in Forced Vital Capacity (FVC) Rate to Week 26 — -0.076; -0.050; -0.136 liters (L)
Phase 2 N=120 Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Part A - Number of Participants With Treatment-Emergent Adverse Events — 1 Participants
Phase 2 N=83 Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis
Primary: Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE…
N/A N=7 Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Acceptability of patientMpower Platform From Patient & Healthcare Professional Perspective — 3; 1; 1; 4 Participants
Phase 2 N=6 A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Effect of Gefapixant on BP — 122; 76 units on a scale
Phase 2 N=23 Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Treatment-Emergent Adverse Events (AEs) — 4; 11 Participants
Phase 1 N=24 A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) — 66.7; 77.8; 50.0; 0 percentage of participants
Phase 3 N=113 Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months — 11.407; 14.583 percent change